Clinical trials open for the enrollment


Title: MK-7902-014/E7080-G000-320/LEAP-014: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080-MK-7902) Plus Chemotherapy In Participants With Metastatic Esophageal Carcinoma

 

Based on the hypothesis that the combination of lenvatinib (tyrosine kinase inhibitor) and pembrolizumab (anti-PD-1) is superior to pembrolizumab alone, this study offers the possibility of associating this combination with standard chemotherapy (fluoropyrimidines and platinum or taxanes and platinum based schemes), comparing it with pembrolizumab in combination with chemotherapy

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Title: DS8201-A-U306 – “A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)”

 

This study offers the possibility of receiving treatment with trastuzumab deruxtecan after progression to an anti-HER2 treatment for patients with gastric or gastroesophageal junction cancer, in comparison with the standard of care (ramucirumab + paclitaxel). This drugs belongs to the innovative category of anti-drug conjugates: specifically, trastuzumab (antibody), by binding to HER2 on tumor cells, allows the penetration of the chemotherapy drug deruxtecan, a topoisomerase I inhibitor.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Title: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”

 

In this trial are investigated efficacy and safety of tisotumab vedotin, antbody- drugconjugate direct against tissutal factor, alone or in association with other drugs, in following neoplasms: colorectal, non-small cell lung cancer, exocrine pancrea, head and neck.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

 

Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.

 

Principal Investigator: Prof. Pierfrancesco Tassone

 

ENROLLMENT ACTUALLY NOT ACTIVE

 


Clinical trials closed for the enrollment

Title: CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Principal Investigator: Prof. Pierosandro Tagliaferri


Title: MK7902-015 – “Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)”

Principal Investigator: Prof. Pierfrancesco Tassone


Title: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri


Title: DZB-CS-202 – “A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)”

Principal Investigator: Prof. Pierfrancesco Tassone